Search

Search Constraints

You searched for: Author/Creator Glass, Jonathan D

Search Results

1. A proteomic network approach across the ALS‐FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. Issue 1 (30th November 2017)

2. ALS‐linked KIF5A ΔExon27 mutant causes neuronal toxicity through gain‐of‐function. (23rd June 2022)

3. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. Issue 2 (3rd June 2016)

4. Erratum to Letters to the Editor regarding: The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy. J Neuropathol Exp Neurol 2021;80(3):210–9. Issue 3 (31st January 2022)

5. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. Issue 4 (31st October 2012)

6. Randomized phase 2 trial of NP001–a novel immune regulator: Safety and early efficacy in ALS. Issue 3 (June 2015)

7. Rare variants in MYH15 modify amyotrophic lateral sclerosis risk. (1st April 2019)

9. Re: The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy. J Neuropathol Exp Neurol 2021;80(3):210–9. Issue 10 (26th October 2021)